



We want to save patients with severe cancer and autoimmune diseases
Clinical investigations with our lead antibody CAN04 to our proprietary target

Göran Forsberg, CEO

Safe Harbour Statement

The following presentation may include predictions, estimates or other information that might be considered forward-looking. The statements regarding the surrounding world and future circumstances in this presentation reflect Cantargia's current thinking with respect to future events and financial performance. Prospective statements only express the assessments and assumptions the company makes at the time of the presentation. These statements are well-considered, but the audience should note that, as with all prospective assessments, they are associated with risks and uncertainties.

Cantargia at a glance

- Specialized in antibody therapy/immunology, with initial focus on oncology
- Lead antibody CAN04 (nidanilimab) in clinical development, pathway clinically validated
- Platform around IL1RAP, lead candidate for autoimmunity and inflammatory disease 2019
- Granted IP - therapeutic target IL1RAP and CAN04
- Strong management team with proven track record in clinical development and business development
- Listed on Nasdaq Stockholm
- Approximately 5000 shareholders
- Based in Lund, Sweden

Financial highlights

- Share price: 15.40 SEK (1.70 USD), Jan 25, 2019
- Market cap: 1019 MSEK (113 MUSD), Jan 25, 2019
- Cash: 191 MSEK (21.3 MUSD), Sep 30 2018

Current owners (Dec 31, 2018)

Sunstone	9.0%
1st AP fund	6.9%
SEB S.A.	5.0%
Avanza Pension	5.0%
4th AP fund	4.6%
Öhman Bank S.A.	4.1%
2nd AP fund	3.3%
Mats Invest AB	2.0%
Tibia konsult	1.9%
Kudu AB	1.9 %
Others	56.3%


Tumor inflammation – key to cancer features



IL-1 blockade in cancer- validating clinical data

CANTOS trial (n=10061)

- Canakinumab (Novartis)
- Reduced lung cancer incidence by 67 % and death by 77 %.



- Clinical validation of IL-1 pathway
- Cantargia's CAN04 has broader MOA

Canakinumab phase 3 trials (compl 20121/2022)

Adjuvant NSCLC (CANOPY-A)

After surgery, no mets, placebo control
1500 patients, recruitment ongoing

First line (CANOPY-1)



Untreated locally advanced/metastatic
Combination Pembro/Platinum doublet
627 patients

Second line metastatic (CANOPY-2)

Previously treated loc adv/metastatic
Combination Docetaxel
240 patients, recruitment ongoing

Source clinicaltrials.gov

CAN04 (nidanilimab) added value vs canakinumab




Canakinumab

- Antibody directed against one of the two IL-1 ligands, IL-1 β

CAN04:

Double mechanism


- Binds the common signaling receptor and counteracts both ligands
- Induce killing via the immune system (ADCC)



CAN04 – CANFOUR clinical trial

Phase I/IIa trial - NSCLC and pancreatic cancer

- Jules Bordet, Brussels; Erasmus Rotterdam, NKI, Amsterdam; Rigshospitalet, Copenhagen; Radiumhospitalet, Oslo
- 22 patients treated:
 - Good safety up to 10 mg/kg
 - Significant effect on relevant biomarkers (IL-6, CRP)
 - 5/13 pts had stable disease up to 6 months
 - NSCLC, pancreatic cancer, colon cancer
- Phase IIa: focused on NSCLC and pancreatic cancer (appr 20 centres)
 - Monotherapy (appr 20 pat)
 - Combination with standard therapy (appr 30 pat per arm)
 - NSCLC Cisplatin/Gemcitabine
 - Pancreatic cancer Gemcitabine/nab-paclitaxel




Dec 2018


Early 2020

Details on www.clinicaltrials.gov

Cantargia pipeline



Medical need and IL1RAP



Size of each indication corresponds to annual deaths in USA

- Cantargia founded based on:
 - Discovery of IL1RAP on cancer cells
 - Antibodies against IL1RAP - antitumor effects
 - Patents on antibody therapy against IL1RAP
- Primary indications. NSCLC and pancreatic cancer
- Biomarker studies ongoing, identify patients most likely to respond
- Opportunity to expand development in additional cancer forms
- Cantargia has granted patent on antibody therapy against IL1RAP

Two major preclinical findings during 2018

-new opportunities

Binding to immune cells in tumor microenvironment



- Antimetastatic effects
- Counteract immune suppression

Synergistic effects with chemotherapy


- Stronger antitumor effects
- Counteracts chemotherapy toxicity

CAN04 surrogate antibody binds to myeloid cells

Localizaiton to tumor (4T1) with low IL1RAP





Myeloid cells in spleen and tumor overexpress IL1RAP





Inflammation and metastasis

- Cancer cells (seeds) need a good soil to form a metastasis
- The IL-1 system (inflammation) can provide such environment (soil)
- Data generated in 4T1 (TNBC) model (n=10)




A tumor can create its own "seed and soil"

Targeting both tumor and endogenous IL1RAP allows synergistic effects with Cisplatin




10 mice per group

CAN04 attacks several cell types in the tumor



Cantargia pipeline




CANTOS additional findings (from Novartis IL-1 β antibody)

CANCER decreased risk of death with treatment (high dose)			
Lung cancer	77 %	P=0.0002	
Non-lung cancer	37 %	P=0.06	
Decreased incidence of inflammatory disease (all doses)			
Arthritis	32%	p<0.0001	
Osteoarthritis	28%	P=0.0005	
Gout	53%	p<0.0001	
Cardiovascular	12%	P=0.02	
Biomarker levels (reduction)			
CRP	26-41%	P<0.0001	
IL-6	25-43%	P<0.001	


IL1RAP - additional potential indications to leverage the value of our asset

- Three different systems signal through IL1RAP
- These systems contribute to various inflammatory diseases
- Can be blocked by Cantargia's antibodies against IL1RAP



Cantargia partnership with Panorama Res Inc (Sunnyvale, CA)
Selection of clinical candidate 2019

Lead project CAN04 in the highest growth segment— Oncology antibodies



Sales cancer therapeutic antibodies 2017 (2016)

Rituxan/MabThera	\$7.87bn	(\$8.58bn)
Avastin	\$7.13bn	(\$6.75bn)
Herceptin	\$7.47bn	(\$6.75bn)

Immuno-oncology driving market growth 2017 (2016)

Opdivo	\$4.95bn	(\$3.77bn)
Keytruda	\$3.81bn	(\$1.40bn)

Source IMS Health & company reported sales

Significant value inflection points ahead of CANFOUR results

2019

- US regulatory and clinical strategy
- Clinical progress and initial phase IIa results
- Preclinical progress (immuno-oncology effects, combinations etc)
- CANxx progress

2020

- Phase IIa results

Cantargia summary

- Lead candidate antibody CAN04 in clinical trials against cancer
 - Encouraging phase I data, phase IIa initiated
 - Double mechanism of action
 - Synergy with chemotherapy
 - Initial development in NSCLC and pancreatic cancer (cancer forms with poor prognosis)
 - Direct effects on tumor cells and tumor microenvironment
 - Recent external validation of pathway
- Second generation antibodies for autoimmune disease
- Unique and strong IP
- Strong lead investors with high competence and well known track record
 - Funding through phase IIa - until mid 2020.